The human luteinizing hormone/chorionic gonadotropin receptor (LHCGR) plays a fundamental role in male and female reproduction. In males, loss-of-function mutations in LHCGR have been associated with distinct degrees of impairment in pre-and postnatal testosterone secretion resulting in a variable phenotypic spectrum, classified as Leydig cell hypoplasia (LCH) type 1 (complete LH resistance and disorder of sex differentiation) and type 2 (partial LH resistance with impaired masculinization and fertility).
Introduction
The human luteinizing hormone/chorionic gonadotropin receptor (LHCGR: OMIM #52790) belongs to the class A G-protein-coupled receptor, and consists of 699 amino acid with a molecular weight of 85-95KDa (1) . Its gene is located on chromosome 2p21 and consists of 12 exons. Exons 1-10 and a part of exon 11 encode for the extracellular domain (ECD), which is responsible for ligand binding. The remaining exon 11 encodes for the transmembrane domain consisting of seven helices (TMH) and the intracellular C-terminal tail, which are involved in signal transduction (2, 3) . The LHCGR transduces intracellular signaling cascades upon activation by the pituitary luteinizing hormone (LH) or the placental human chorionic gonadotrophin (hCG). Its role is fundamental in male and female fetal sex differentiation and reproductive physiology (4).
Indeed, homozygous or compound heterozygous loss-of-function mutations in the LHCGR gene have been described in males and females and have provided important insights into distinct physiological roles of LH in reproduction of both sexes (5) . Depending on the severity of the LHCGR inactivation, a variable spectrum of disorders of sex differentiation (DSDs) has been described (6) . In Leydig cell hypoplasia (LCH, OMIM #238320), male to female DSD and absence of sexual maturation at puberty are the phenotypic features of 46,XY patients with the severe form of LHCGR resistance, also called LCH type 1. Patients with milder forms of resistance, LCH type 2, have micropenis and/or hypospadias or only infertility without sexual ambiguity. These patients present low testosterone levels unresponsive to the rise of endogenous LH concentrations after pubertal age or to exogenous hCG stimulation associated to only slight reduction in testes size but with variable LCH. Currently, more than 30 LHCGR variants have been identified with variable loss-offunction (1) . These inactivating variations are scattered throughout the different domain of the LHCGR, either the ECD or the TMH or the C-terminal tail. Very recently a 27 bp deletion was detected in exon 1 at amino acid number 12 involving the signal peptide region of the LHCGR (7) . Nevertheless, no specific functional studies were provided in this report regarding the role of the LHCGR signal peptide. Here, we report a new case of LCH type 2 due to a biallelic defect in the LHCGR gene. One substitution, p.S616Y, was previously described in a patient with LCH (8) , while the second one, p.L10P, is a novel substitution located in the putative signal peptide of LHCGR. In this work, we have functionally characterized the LHCGR receptor signal peptide and the impact of p.L10P substitution. We show that the signal peptide of LHCGR is indeed necessary for receptor expression and trafficking, but not for the formation of a functional receptor entity and at UniversitÃ degli Studi di Milano on http://hmg.oxfordjournals.org/ Downloaded from that p.L10P variant strongly impair receptor biogenesis.
Results

Patient characterization and genetic analysis
The patient, a 46 XY male, presented at birth with micropenis, cryptorchidism and hypospadias. At 5 years of age, he underwent surgery for bilateral cryptorchidism. At 12 years, he came to the pediatric endocrinologist for the evaluation of auxological parameters and pubertal development: his height was >97°percentile and weight >97°percentile, the Tanner stage was PH3 with a testicular volume of 4 ml bilaterally and defective penis length (2 cm; <2.5 SDS for age). Hormonal evaluation showed prepubertal total Testosterone (T <0.69 nmol/L) with slight elevation of gonadotropin levels (LH=10.9 IU/L; FSH=6.5 IU/L), and an exaggerated response of LH to GnRH test and a poor increase of T to hCG stimulation (see Fig.1A ). A second evaluation at the age of 15 years showed primary hypogonadism (LH=40.8 IU/L; FSH=16.0 IU/L; total T= 4.09 nmol/L, Fig.1A) . No other hormonal deficiencies were present. Testis biopsy showed profound Leydig cell hypoplasia and absent germinal cells. The sequence analysis of the LHCGR gene showed the presence of a compound heterozygosity: one variation, c.1847C>A (p.S616Y), was previously described in association to LCH (8, 9) , and the other, c.29 C>T (p.L10P), revealed to be a new variant (Fig.1B) .
Investigations in the family, revealed that the two parents were heterozygous carriers of the two variants, with paternal allele encoding the p.S616Y variant and the maternal allele carrying the new variant. The normal phenotype of the parents indicates that one functional allele of the LHCGR gene is sufficient for normal LHCGR function and reproductive processes.
The p.L10P variant do not completely abolish LHCGR activity but affect receptor expression
In a cAMP stimulation assay on COS7 cells transfected with the wild type (WT) LHCGR or p.L10P variant, the cells expressing the p.L10P construct respond to hCG with a reduced Emax (to 58.6% of the WT level) and an equal EC 50 (0.063 IU/L versus 0.064 IU/L) in comparison with the wild-type LHCGR (Fig.2A) .
The level of receptor expression on the cell surface was then investigated by immunofluorescence, using a specific antibody directed against a linear epitope mapping in the LHCGR ECD, but far from the N-terminal domain where is located the mutant p.L10P. As shown in Fig. 2B , the wild type LHCGR is correctly expressed and trafficked on the cell surface, whereas the L10P substitution results in a significant reduction of receptor expression level. The WT LHCGR expression was also quantified through flow cytometry in non- (Fig.2C ) and we show that the cell surface amount of the p.L10P mutant is largely reduced to 14.6 ± 2.17% (P < 0.001, ANOVA) of the WT receptor. Similarly, the total receptor expression amount of p.L10P in permeabilized cells (Fig.2D ) is drastically impaired (26.3 ± 1.34% (P < 0.001, ANO-VA) of the WT receptor), while the total receptor expression of p.S277L variant, already known to be an intracellular retained mutant (10) , is similar to WT. The ratios between membrane associated/intracellular receptors (panel 2E) are consistent with a prevalent trafficking defect for p.S277L and a prevalent synthesis defect for p.L10P. 
The putative signal peptide of LHCGR is functional and cleavable
Because the p.L10P mutation is located in the hydrophobic region of the putative signal peptide of LHCGR, (11, 12) (Fig.3A) . The likelihood of the identified signal peptide in WT receptor sequence is very high (0.966) and the maximal cleavage site probability (cp) occurs between residues Ala24 and Leu25 (probability: 0.662). According to the computational analyses, the p.L10P substitution affects both of the above mentioned parameters: signal peptide and maximal cleavage site probability are decreased at 0.702 and 0.286, respectively.
To assess whether the putative signal peptide of the LHCGR receptor is functional, the sequence for the N tail of the receptor with signal peptide was fused with a His-tagged GFP as a soluble marker protein. Constructs containing the N tail of the CRF-R1 (Corticotropin-Releasing Factor Receptor 1) and CRF-R2a (Corticotropin-Releasing Factor Receptor 2a) were used as positive and negative controls, respectively. Alken and colleagues (13) report that if a cleavable signal peptide is present in the N-terminal domain of the LHCGR receptor, it should direct the soluble GFP marker to the endoplasmic reticulum (ER) and subse-quently via the secretory pathway to the cell culture medium. On the opposite, if the sequence does not contain a functional signal peptide, the marker protein is expected to remain in the cytosol. According to this approach, we transiently transfected COS7 cells with these constructs and the GFP fluorescence signals were localized by confocal LSM (Fig.3B) . In case of the WT LHCGR receptor and CRF-R1 positive control, reticular signals and a GFP-free nucleus (Fig.3B) can be detected, indicating that the fusion protein is directed to the ER membrane and into the ER lumen. Moreover the presence of the GFP protein in the cell culture medium (Fig.3C) shows that the N-terminal domain of LHCGR contains a cleavable signal peptide. In contrast, cytosolic and nuclear GFP signals are seen in the case of p.L10P mutant and CRF-R2a negative control, indicating that the mutant signal peptide is unable to mediate ER targeting/insertion of heterologous proteins.
Specific mutations at position 10 of the LHCGR signal peptide are not predicted to disturb the secondary structure
The potential effect of the p.L10P mutation on the LHCGR structure was estimated by assembling a complex model between the signal recognition particle protein (SRP) and the signal peptide of the LHCGR. Three subsequent portions (the n-, the h-and the c-region) generally constitute the signal peptides (see Fig.4A ). Amino acids in the h-region of the signal peptide ( Fig.4A ) are in a α-helical conformation, but the helix probably extends to Arg23, with a bend at Pro19 and Pro20. It's worth noting that three glutamates of the SRP M domain are interacting in complementation with positively charged residues of a M domain loop structure and arginines of the LHCGR SP C-terminus (Fig.4A) . The p.L10P substitution is located at the transition between the n-and the h-region of the SP. The n-region includes also few hydrophilic residues like Gln9, which can interact with a glutamine at the SRP M domain. However, the hydrophobic part of the SP is likely responsible for the correct relative orientation of the components (15) . This orientation is finally also critical for justifying of the M domain relative to the exit channel in the ribosome. The simulated substitution of Leu10 to Pro10 in a complexed SRP/SP structure results only in a slight modification of the SP backbone, however proline substitutions are known to induce structural modifications like helix-kinks (16) . In order to asses and to distinguish if changes in biophysical properties or structural prerequisites at this position are critical for the SP function, we created three additional "in silico" variants and experimentally tested the expression of the mutated LHCGR receptor by western blot analyses. A marked reduction of receptor expression is observed also when the leucine at position 10 is substituted by the polar amino acid serine (Fig.4B) .
Indeed the p.L10S substitution should lead to different SRP/SP interaction pattern, like with hydrophilic amino acids at the M domain, which would finally cause a dis-arrangement of the general complex architecture. We therefore conclude, that the change in biophysical properties like hydrophobicity at this position is responsible for observed dysfunction, rather than drastic changes in the secondary SP structure.
The pL10P variant is recovered by MG132 treatment
Typically, a cleavable signal peptide mediates ER targeting/insertion of the nascent chains. Therefore, the reduced expression of the p.L10P mutant may result either from an impaired ER targeting/insertion of the receptor with an abnormal signal peptide, or from decreased transcription or translation. To exclude the latter alternative, we performed Real Time PCR experiments with total RNA derived from transiently transfected COS7 cells (Fig.5A ). Both transcripts were present in similar amounts, demonstrating that differences in transcription do not account for the reduced expression of the signal peptide mutant.
Taken together, our results indicate that the signal peptide of LHCGR improves one of the early steps of receptor biogenesis such as targeting and/or insertion. We thus speculate that the p.L10P substitution could impair receptor biogenesis leading to a premature degradation of the immature receptor. To test this hypothesis, COS7 cells transfected with the wild type and the p.L10P construct were treated with the proteasome inhibitor MG132 24 hours after transfection. Accordingly, treatment with MG132 leads to accumulation of a lower molecular weight form (approximatively 65 kDa) in cells transfected with the p.L10P mutant compared to the WT counterpart (Fig 5B) . Moreover, immunofluorescence experiments shows the appearance of an intracellular signal in cells transfected with the construct p.L10P following the treatment with the proteasome inhibitor MG132 (Fig 5C) . To further investigate the nature of this lower molecular weight form, the lysates of MG132-treated cells were digested with PNGaseF, a glycosidase that removes all types of Nlinked glycans (Fig 5D) . In accordance with previous published data (17) , PNGaseF treatment affects electrophoretic mobility of the two distinct WT-LHCGR species leading to the accumulation of a ~ 62 KDa lower band. On the contrary, the PNGaseF treatment does not affect the molecular weight of the ~65-kDa band observed in cells transfected with the p.L10P, indicating that the p.L10P protein should not be able to translocate into the ER lumen but is rather located in the cytosol, where it cannot be glycosylated in accordance with the GFP targeting experiments. Furthermore, the shift of the two different molecular species of WT-LHCGR to a smaller size (~ 62 KDa) indicates that this protein species has undergone signal peptide cleavage, whereas the p.L10P 65-kDa fragment has not.
Discussion
We describe the functional impact of the new p.L10P substitution in the signal peptide of LHCGR that was found in a male adolescent with LCH type 2. The sequence analysis of the LHCGR gene in this patient revealed a compound heterozygosity, between p.S616Y and p.L10P inherited from the unaffected heterozygous mother and father, respectively. Indeed, the in vitro results here shown, including the experiments after co-expression of the different LHR isoforms (wt and/or L10P and/or S616Y) (see Supplemental Figure 1 ), correlate well with the clinical expression of the disease in the family. Because the p.L10P insertion is located in the hydrophobic region of the putative signal peptide of LHCGR, we thought that the decreased receptor activity and expression ( Fig.2A-D) might result from an altered function of the signal peptide itself.
Few data are presently available on the role of the signal peptide in the GPCR field. One possible role is to mediate the translocation across the ER membrane if the N-terminal domain of a receptor cannot be translocated post-translationally, as previously reported for the endothelin B receptor (18) . Removal of such a signal peptide leads to abnormally folded and non-functional receptors. A second role, as described for CRF-R1, is to modulate receptor expression by a still incompletely understood mechanism (13) . In the CRF-R1, the signal peptide precedes the N-terminal domain that can be translocated post-translationally, but it is not required for the formation of a functional receptor.
In the present study, we provide a functional characterization of the cleavable signal peptide in LHCGR. We show that an abnormal signal peptide does not completely abolish the LHCGR activity as both the wild-type and the SP-mutant receptors were able to stimulate the adenylate cyclase system without significant changes in the EC 50 (0,064 versus 0,063 IU/L) ( Fig.2A) . However, the signal peptide has a strong impact on receptor expression. Western blot experiments, FACS analysis and confocal laser scanning microscopy ( Fig.2B-D) consistently revealed that expression of the p.L10P mutant is decreased by 70-80%. Since a mechanism for specific mRNA degradation in response to the synthesis of defective proteins was recently reported (13, 19) , we have also excluded the possibility that the sequence encoding the signal peptide has an effect on mRNA level or translation efficiency (see Fig.5A ).
Thus the LHCGR signal peptide influences one of the processes of the early secretory pathway. It may facilitate targeting of the nascent chain-SRP-ribosome complex to the ER membrane or alternatively prevent an early degradation process. We explored the potential effect of this mutation on the protein structure assembling by a structural homology complex between the signal recognition particle protein (SRP) and the signal peptide of the LHCGR. The simulated substitution of Leu10 to Pro10 in a complexed SRP/SP structure results only in a slight modification of the SP backbone. However, based on insights from the model in combination with mutagenesis studies (e.g. Leu10Ser) we speculate, that the change in biophysical properties like hydrophobicity at this position has effects on component justification (de-justification), which is likely responsible for the SP malfunction in the interaction with the SRP.
Typically, the signal peptide sequence is co-translationally recognized by SRP (20) . The ribosome-nascent chain-SRP complex is targeted to its receptor in the ER membrane where the nascent chain is translocated into ER lumen by the Sec61p/TRAM translocon, and finally the signal sequence is removed by signal peptidase (13, (21) (22) (23) . Based on our data, we hypothesize that the p.L10P mutation causes a disarray in the assembling of the SRP/SP complex, thus interfering with the translocation of the nascent receptor chain into ER lumen.
The experiments addressing signal peptide functionality of the p.L10P mutant strongly suggest that its signal peptide is completely non-functional. However, the cAMP accumulation assay revealed that minor amounts of the mutant are nevertheless present at the plasma membrane. On the one hand, these results indicate that the signal peptide of the LHCGR is not an absolute requirement for a functional receptor similar to the signal peptide of the CRF-R1 previously described (13) . On the other hand, these results raise the question on the rescue mechanism allowing minor amounts of the p.L10P mutant to reach the ER and consequently the plasma membrane. In the absence of a functional signal peptide, the transmembrane segment 1 (TM1) of the receptor could take over the ER targeting/insertion functions as a signal anchor sequence. In the case of the p.L10P mutant, one may speculate that a small ancillary functional population could be successfully integrated into the ER membrane by the signal anchor sequence mechanism and reach the plasma membrane.
This might be also dependent on the fact that we are working in heterologous cell system with an overex- pression of the mutant receptor and not in the natural host cells. However our data suggest that both ER targeting/insertion or N tail translocation are mainly defective also by using such rescue mechanism. In the case of the p.L10P mutant the larger receptors population may not even reach the ER membrane or may be misfolded due to an impaired N-terminal domain translocation. These receptors would be present in their nonglycosylated form in the cytosol, rapidly degraded by the proteasome and consequently stabilized by MG132 treatment (Fig.5C ).
In conclusion, we provide the first experimental evidences that LHCGR have a functional and cleavable signal peptide required for receptor biogenesis. Moreover, our in vitro results demonstrate the pathogenic role of the novel p.L10P allelic variant, which is to be considered a novel loss-of-function mutation significantly contributing, in compound heterozygosity with the p.S616Y mutation, to the Leydig cell hypoplasia type 2 observed in our patient.
Materials & Methods
DNA isolation and sequencing analysis
Genomic DNA from the patient and his parents was extracted from peripheral blood using the QIAamp DNA Blood Mini Kit (Qiagen Inc., Valencia, CA, USA) and stored at -20°C until use. Written informed consent was obtained from all the subjects. Exons of the LHCGR gene (GeneBank accession number NM_000233. 3) were amplified by PCR with intron spanning primers as previously described (24) . Genomic DNA was sequenced using a CEQ Dye-Terminator Cycle Sequencing kit (Beckman Coulter Inc., Miami, FL, USA) according to the manufacturer's protocol. Sequence alignments were performed with DNAStar program (DNAStar Inc., Madison, WI, USA). Sequences with DNA variations were confirmed from a separately DNA extraction, PCR amplification and sequence reaction. All the sequence reactions were performed using a CEQ XL2000 DNA Analysis System (Beckman Coulter).
Mutant expression vectors
Plasmid pSVL-hLHCGR (25) In short, after substitution of the amino-acids from the LHCGR into the determined peptide structure, the peptide and M domain were energetically minimized until converging at a termination gradient of 0.05 kcal/mol*Å, by fixing the backbone atoms and by using the AMBER 7 force field. This step was followed by a dynamic simulation of 1.5 ns with restraint backbone atoms to justify the side-chains optimal to each other. A further dynamic simulation step was proceeded for 0.5 ns without any constraints on the protein structure. The resulting entire system was again minimized. This protocol was repeated with the bound L10P variant starting with the initial substitution step. We also performed single SP peptide modifications without the M domain. For this purpose the original SP peptide was extracted from the complex structure and the LHCGR side-chains were substituted, for wild type and the L10P mutant. The dynamic simulation (2 ns) of 
